1. Scrip
  2. >>Business

Why Kevin Lee Left Pfizer To Push Bicycles

 
• By Sukaina Virji

The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.

The pharma wires have been busy recently with news of droves of big pharma executives leaving their posts to take up the top spot at small biotech companies. The latest is Dr Kevin Lee, the former chief scientific officer of the Rare Disease Research Unit at Pfizer. Here he tells Scrip's Sukaina Virji what prompted him to leave the glamorous life of a big pharma executive and take up his new job as chief executive officer of tiny Cambridge, UK-based biotech Bicycle Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Ironwood To Consider All Options With Apraglutide Setback In SBS

 
• By Joseph Haas

With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation

 
• By Jessica Merrill

The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

More from Scrip

Pipeline Watch: Ten Approvals And Eleven Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

US Tariffs And Manufacturing Concentration: Double-Edged Sword?

 
• By Anju Ghangurde

India and the US are the major manufacturers of finished dosages for the US market in terms of volume (China accounts for 9% of injectables), though the US relies heavily on India for solid oral dosage forms and specific generics, including lenalidomide and albuterol. Scrip talks to experts on some of the key implications of geographic concentration of production for the US market amid the specter of tariffs.